Synaptogenix Inc (SNPX)

[resident1]

NTRP looks opposite to what you are describing, except for the high inside ownership.

NTRP is not dragging out the process. They executed a relatively quick blinded placebo controlled trial. If they wanted to drag it out they would have done more safety studies that weren't designed as powered studies or with enough drug to show efficacy, again, to drag things out. They would have done it in mildly affected patients where it's hard to tell if they have Alz, and hard to tell if it's effective or not since the people are kind of still ok. If this study fails, their large inside ownership will quickly become almost worthless and they walk away with Nothing.

I don't see the scam here. They didn't leave themselves room to execute on the scam; none of the other requirements have been put in place.

I am invested in other biotechs where there are stock incentives to management. The "goals" are easily set by the same management and met 100% each year, even though the stock actually lost value, since conveniently that was not one of the goals to increase shareholder value. So among other reasons, I don't really care about this point since it can be manipulated just as much when the management and board are all fellows of the Executive Club that like to scratch each other's backs.

Unfortunately, this does seem to be the way NTRP is working out.. High insider ownership, whereas that "other" stock has high retail ownership backed by stock incentives to management.

Quote:

Some bio investors are only looking at how long the process can be drug out. It is like a ponzi scheme, where they get in low, the company runs endless meaningless trials. The retail investors get sucked in and the low price insider and option holders walk away in a few years with money in the bank.